Clinical Trials Logo
  1. Home
  2. Influenza Vaccines
  3. NCT02358083
  4. Details
NCT02358083 Clinical Trial

Attitudes Toward Human Papillomavirus and Influenza Vaccination Among Mothers of Early Adolescents

Influenza Vaccines Clinical Trial

Official title:
Attitudes Toward Human Papillomavirus and Influenza Vaccination Among Mothers of Early Adolescents

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02358083
Other study ID # 8645194
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 2014
Est. completion date August 2014

Study information
Verified date October 2023
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study was to determine whether messages about 1. relative risk of vaccination vs. other activities and 2. strength of doctor's recommendation influenced parental intention to get own child vaccinated against human papillomavirus (HPV) or Influenza.

Recruitment information / eligibility
Status Completed
Enrollment 1165
Est. completion date August 2014
Est. primary completion date August 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years of age or older - Lives in United States - Mother or female legal guardian of at least one child aged 9-13 - Able to understand English - For HPV condition: Target child must not have received any doses of HPV vaccine - For Flu condition: Target child must not have received the flu vaccine during the prior flu season Exclusion Criteria: - Under 18 years of age - Not mother or female legal guardian of at least one child ages 9-13 - Not living in United States - Not able to understand English and Spanish - For HPV condition: Target child had already received at least 1 dose of the HPV vaccine - For Flu condition: Target child received the influenza vaccine during the previous flu season

Study Design

Related Conditions & MeSH terms

Intervention

Behavioral:
• Provider Communication about Vaccination
There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Indiana University

Outcome
Type Measure Description Time frame Safety issue
Primary Willingness to vaccinate child with target vaccine During survey administration, at approximately 15 minutes into the survey.
See also
  Status Clinical Trial Phase
Completed NCT03246100 - Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates_2nd Trial in Colorado N/A
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT02761551 - Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates N/A
Recruiting NCT05298800 - Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 Phase 4
Completed NCT03735147 - Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in Children Phase 4
Completed NCT02831608 - Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis Phase 4
Completed NCT02560909 - Adjuvanted Influenza Vaccine in Stem Cell Transplant Phase 4
Withdrawn NCT01623232 - MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly Phase 1/Phase 2
Completed NCT00961337 - Evaluation of a School-based Influenza Vaccination Program Phase 4
Completed NCT00402805 - Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy Phase 4
Completed NCT00222638 - Influenza Vaccination and Oral Anticoagulant Therapy Phase 4
Active, not recruiting NCT03734237 - A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD Phase 4
Completed NCT01013675 - Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly Phase 2
Completed NCT00306995 - Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population Phase 2
Completed NCT01310413 - Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age Phase 3
Completed NCT00449670 - Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults Phase 3
Completed NCT01788228 - Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure Phase 3
Completed NCT00296270 - Memory for Flu Facts and Myths and Effects on Vaccine Intentions N/A
Recruiting NCT05521763 - Influenza Vaccine Uptake Among Healthcare Workers N/A
Completed NCT00718120 - Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years Phase 3